Treat Now or Treat Later: Comparative Effectiveness of Adjuvant Therapy in Resected Stage IIIA Melanoma
- 28 February 2022
- journal article
- conference paper
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 234 (4) , 521-528
Abstract
Export BACKGROUND: Adjuvant therapy for most sentinel-node–positive (stage IIIA) melanoma may have limited clinical benefit for older patients given the competing risk of non-cancer death. The objective of this study is to model the clinical effect and cost of adjuvant therapy in stage IIIA melanoma across age groups. STUDY DESIGN: A Markov decision analysis model simulated the overall survival of patients with resected stage IIIA melanoma treated with adjuvant therapy vs observation. In the adjuvant approach, patients are modeled to receive adjuvant pembrolizumab (BRAF wild type) or dabrafenib/trametinib (BRAF mutant). In the observation approach, treatment is deferred until recurrence. Transition variables were derived from landmark randomized trials in adjuvant and salvage therapy. The model was analyzed for age groups spanning 40 to 89 years. The primary outcome was the number needed to treat (NNT) to prevent one melanoma-related death at 10 years. Cost per mortality avoided was estimated using Medicare reimbursement rates. RESULTS: Projections for NNT among BRAF wild type patients increased by age from 14.71 (age 40 to 44) to 142.86 (age 85 to 89), with patients in cohorts over the age of 75 having an NNT over 25. The cost per mortality avoided ranged from $2.75 million (M) (age 40 to 44) to $27.57M (age 85 to 89). Corresponding values for BRAF mutant patients were as follows: NNT 18.18 to 333.33; cost per mortality avoided ranged from $2.75M to $54.70M. CONCLUSION: Universal adjuvant therapy for stage IIIA melanoma is costly and provides limited clinical benefit in patients older than 75 years.Keywords
This publication has 23 references indexed in Scilit:
- Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United StatesJournal of Medical Economics, 2019
- Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patientsAnnals of Oncology, 2019
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaNew England Journal of Medicine, 2018
- Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patientsBMC Cancer, 2018
- Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated MelanomaNew England Journal of Medicine, 2017
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine, 2017
- Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011Cancer Medicine, 2017
- Completion Dissection or Observation for Sentinel-Node Metastasis in MelanomaNew England Journal of Medicine, 2017
- Stage-specific prognostic biomarkers in melanomaOncotarget, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibNew England Journal of Medicine, 2015